title: Pediatric acute myeloid leukemia as classified using 2008 WHO criteria: a single-center experience.
abstract: The classification of acute myeloid leukemia (AML) has evolved to the most recent World Health Organization (WHO) schema, which integrates genetic, morphologic, and prognostic data into a single system. However, this system was devised using adult data and how this system applies to a pediatric cohort is unknown. Performing a retrospective chart review, we examined our single-center experience with AML in 115 children and classified their leukemia using the WHO 2008 schema. We examined patient samples for mutations of FLT3, NPM1, and CEBPA. Overall survival was calculated within categories. In our pediatric population, most cases of AML had recurrent genetic abnormalities of favorable prognosis. More than 10% of patients in our series were categorized as AML, with myelodysplasia-related changes, an entity not well-described in pediatric patients. In addition, a large proportion of patients were categorized with secondary, therapy-related AML. To our knowledge, this is the first application of the WHO 2008 classification to a pediatric cohort. In comparison to adult studies, AML in the pediatric population shows a distinct distribution within the WHO 2008 classification.
authors.affiliation: Stanford University Medical Center, Dept of Pathology, Stanford, CA 94305, USA.
authors.forename: Kara L
authors.initials: KL
authors.lastname: Davis
authors.forename: Neyssa
authors.initials: N
authors.lastname: Marina
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Arber
authors.forename: Lisa
authors.initials: L
authors.lastname: Ma
authors.forename: Athena
authors.initials: A
authors.lastname: Cherry
authors.forename: Gary V
authors.initials: GV
authors.lastname: Dahl
authors.forename: Amy
authors.initials: A
authors.lastname: Heerema-McKenney
mesh_terms: D000293:Adolescent; D022762:CCAAT-Enhancer-Binding Proteins / Q000032:analysis / Q000235:genetics; D002648:Child; D002675:Child, Preschool; D004314:Down Syndrome / Q000150:complications; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D015470:Leukemia, Myeloid, Acute / Q000145:classification* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D009190:Myelodysplastic Syndromes / Q000235:genetics; D009687:Nuclear Proteins / Q000032:analysis / Q000235:genetics; D000090243:Nucleophosmin; D012189:Retrospective Studies; D012306:Risk; D014944:World Health Organization; D055815:Young Adult; D051941:fms-Like Tyrosine Kinase 3 / Q000032:analysis / Q000235:genetics
chemical_list: D022762:CCAAT-Enhancer-Binding Proteins; C515848:CEBPA protein, human; C000716967:NPM1 protein, human; D009687:Nuclear Proteins; D000090243:Nucleophosmin; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3
keywords: Acute myeloid leukemia (AML); Pediatric; Therapy-related AML; WHO classification